Published in Schizophr Res on September 01, 2002
Word use in first-person accounts of schizophrenia. Br J Psychiatry (2014) 2.59
Sense of agency in health and disease: a review of cue integration approaches. Conscious Cogn (2011) 1.48
Separable forms of reality monitoring supported by anterior prefrontal cortex. J Cogn Neurosci (2008) 1.24
Self-recognition deficits in schizophrenia patients with auditory hallucinations: a meta-analysis of the literature. Schizophr Bull (2010) 1.21
Development of rostral prefrontal cortex and cognitive and behavioural disorders. Dev Med Child Neurol (2008) 1.13
Habitual prospective memory in schizophrenia. BMC Psychiatry (2003) 1.10
A neuropsychiatric model of biological and psychological processes in the remission of delusions and auditory hallucinations. Schizophr Bull (2006) 1.07
First-rank symptoms in schizophrenia: reexamining mechanisms of self-recognition. Schizophr Bull (2008) 1.05
The perceptual characteristics of voice-hallucinations in deaf people: insights into the nature of subvocal thought and sensory feedback loops. Schizophr Bull (2006) 1.00
A specific brain structural basis for individual differences in reality monitoring. J Neurosci (2011) 0.95
Self-disturbances as a possible premorbid indicator of schizophrenia risk: a neurodevelopmental perspective. Schizophr Res (2013) 0.91
Functional magnetic resonance imaging of internal source monitoring in schizophrenia: recognition with and without recollection. Schizophr Res (2006) 0.90
The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology (2006) 0.88
Distinguishing familiarity-based from source-based memory performance in patients with schizophrenia. Schizophr Res (2007) 0.86
Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology (Berl) (2005) 0.85
The reality monitoring deficit as a common neuropsychological correlate of schizophrenic and affective psychosis. Behav Sci (Basel) (2013) 0.85
Me, myself and I: temporal dysfunctions during self-evaluation in patients with schizophrenia. Soc Cogn Affect Neurosci (2013) 0.84
Levels-of-processing effect on internal source monitoring in schizophrenia. Psychol Med (2006) 0.81
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. Psychopharmacology (Berl) (2003) 0.79
Source retrieval is not properly differentiated from object retrieval in early schizophrenia: an fMRI study using virtual reality. Neuroimage Clin (2014) 0.78
Neurocognitive predictors of source monitoring in schizophrenia. Psychiatry Res (2012) 0.78
Paracingulate sulcus morphology is associated with hallucinations in the human brain. Nat Commun (2015) 0.78
Monitoring what is real: The effects of modality and action on accuracy and type of reality monitoring error. Cortex (2016) 0.78
Selective attention impairment in Schizophrenia: can it explain source monitoring failure? J Nerv Ment Dis (2010) 0.77
Misattributing the Source of Self-Generated Representations Related to Dissociative and Psychotic Symptoms. Front Psychol (2016) 0.76
Reality monitoring impairment in schizophrenia reflects specific prefrontal cortex dysfunction. Neuroimage Clin (2017) 0.75
Reality monitoring and its association with social functioning in schizophrenia. Psychiatry Res (2010) 0.75
Impaired Self-Monitoring of Inner Speech in Schizophrenia Patients with Verbal Hallucinations and in Non-clinical Individuals Prone to Hallucinations. Front Psychol (2016) 0.75
Structural MRI Differences between Patients with and without First Rank Symptoms: A Delusion? Front Psychiatry (2015) 0.75
Considerations for analysis of source monitoring data when investigating hallucinations in schizophrenia research. Eur Arch Psychiatry Clin Neurosci (2010) 0.75
Mistiming of thought and perception predicts delusionality. Proc Natl Acad Sci U S A (2017) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
The genome of S-PM2, a "photosynthetic" T4-type bacteriophage that infects marine Synechococcus strains. J Bacteriol (2005) 2.52
Giant virus with a remarkable complement of genes infects marine zooplankton. Proc Natl Acad Sci U S A (2010) 2.34
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Single-cell genomics reveals organismal interactions in uncultivated marine protists. Science (2011) 1.90
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Categorial compositionality: a category theory explanation for the systematicity of human cognition. PLoS Comput Biol (2010) 1.85
Validity and reliability of self-reported arthritis: Georgia senior centers, 2000-2001. Am J Prev Med (2005) 1.80
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Genetic diversity of marine Synechococcus and co-occurring cyanophage communities: evidence for viral control of phytoplankton. Environ Microbiol (2005) 1.70
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Annotation of environmental OMICS data: application to the transcriptomics domain. OMICS (2006) 1.62
Virus succession observed during an Emiliania huxleyi bloom. Appl Environ Microbiol (2003) 1.59
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
Use of microarrays to assess viral diversity: from genotype to phenotype. Environ Microbiol (2007) 1.55
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
A multinomial model of event-based prospective memory. J Exp Psychol Learn Mem Cogn (2004) 1.52
The "Cheshire Cat" escape strategy of the coccolithophore Emiliania huxleyi in response to viral infection. Proc Natl Acad Sci U S A (2008) 1.49
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
Catatonic coma with profound bradycardia. Psychosomatics (2007) 1.38
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet (2009) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37
Molecular dynamics of Emiliania huxleyi and cooccurring viruses during two separate mesocosm studies. Appl Environ Microbiol (2006) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
What do transitive inference and class inclusion have in common? Categorical (co)products and cognitive development. PLoS Comput Biol (2009) 1.35
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis (2006) 1.32
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull (2003) 1.30
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
Expression of a novel marine viral single-chain serine palmitoyltransferase and construction of yeast and mammalian single-chain chimera. J Biol Chem (2006) 1.27
Impairment of social perception associated with lesions of the prefrontal cortex. Am J Psychiatry (2004) 1.26
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol (2004) 1.23
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res (2005) 1.20
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
The source of adult age differences in event-based prospective memory: a multinomial modeling approach. J Exp Psychol Learn Mem Cogn (2006) 1.19
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr Res (2006) 1.19
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res (2009) 1.17
The effects of working memory resource availability on prospective memory: a formal modeling approach. Exp Psychol (2005) 1.14
The cognitive processes underlying event-based prospective memory in school-age children and young adults: a formal model-based study. Dev Psychol (2010) 1.12
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr Serv (2006) 1.12
Categorial compositionality II: universal constructions and a general theory of (quasi-)systematicity in human cognition. PLoS Comput Biol (2011) 1.10
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv (2006) 1.09
Locus-specific gene expression pattern suggests a unique propagation strategy for a giant algal virus. J Virol (2006) 1.09
A unicellular algal virus, Emiliania huxleyi virus 86, exploits an animal-like infection strategy. J Gen Virol (2009) 1.09
Evolutionary history of the Coccolithoviridae. Mol Biol Evol (2005) 1.08
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry (2004) 1.04
Genome sequence of Ostreococcus tauri virus OtV-2 throws light on the role of picoeukaryote niche separation in the ocean. J Virol (2011) 1.04
Relational knowledge: the foundation of higher cognition. Trends Cogn Sci (2010) 1.04
Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav (2003) 1.03
From small hosts come big viruses: the complete genome of a second Ostreococcus tauri virus, OtV-1. Environ Microbiol (2009) 1.03
Characterization of a latent virus-like infection of symbiotic zooxanthellae. Appl Environ Microbiol (2007) 1.03
Genome comparison of two Coccolithoviruses. Virol J (2006) 1.02
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol (2008) 1.02
The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry (2008) 1.02
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett (2005) 1.02
Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res (2002) 0.99
Categorial compositionality III: F-(co)algebras and the systematicity of recursive capacities in human cognition. PLoS One (2012) 0.97
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc (2008) 0.96
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry (2002) 0.95
What can the diffusion model tell us about prospective memory? Can J Exp Psychol (2011) 0.94
The multinomial model of prospective memory: validity of ongoing-task parameters. Exp Psychol (2011) 0.94
Age effects in emotional prospective memory: cue valence differentially affects the prospective and retrospective component. Psychol Aging (2011) 0.93
Genome Sequence of the Sulfitobacter sp. Strain 2047-Infecting Lytic Phage {Phi}CB2047-B. Genome Announc (2014) 0.93
Encapsidation of host DNA by bacteriophages infecting marine Synechococcus strains. FEMS Microbiol Ecol (2003) 0.92
Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. Clin Schizophr Relat Psychoses (2012) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med (2008) 0.92
Host-virus shift of the sphingolipid pathway along an Emiliania huxleyi bloom: survival of the fattest. Environ Microbiol (2009) 0.91
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res (2011) 0.91
When is schematic knowledge used in source monitoring? J Exp Psychol Learn Mem Cogn (2002) 0.90
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry (2004) 0.89
Adult age differences in distinctive processing: the modality effect on false recall. Psychol Aging (2005) 0.89
Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res (2011) 0.89
Identification of a diagnostic marker to detect freshwater cyanophages of filamentous cyanobacteria. Appl Environ Microbiol (2006) 0.88
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry (2009) 0.87
Smoking and psychosis in patients with bipolar I disorder. Compr Psychiatry (2002) 0.87